RT Journal Article
SR Electronic
T1 Early onset leprosy reveals a joint effect of <em>LRRK2</em> and <em>NOD2</em> variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.25.21253623
DO 10.1101/2021.03.25.21253623
A1 Dallmann-Sauer, Monica
A1 Xu, Yong Zhong
A1 da Costa, Ana Lúcia França
A1 Tao, Shao
A1 Correa-Macedo, Wilian
A1 Manry, Jérémy
A1 Abel, Laurent
A1 Alcaïs, Alexandre
A1 Cobat, Aurélie
A1 Fava, Vinicius M.
A1 Probst, Christian M.
A1 Mira, Marcelo T.
A1 Schurr, Erwin
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.25.21253623.abstract
AB Leprosy, caused by Mycobacterium leprae, has a long incubation period and cases with age-of-onset &lt;5 years are rare. Here, we studied a three-generational multiplex leprosy family which included monozygotic twins age &lt;24 months suffering from paucibacillary leprosy. Whole genome sequencing identified a homozygous double mutation in the LRRK2 gene (N551K, R1398H) and a heterozygous mutation in NOD2 (R702W) as candidate variants underlying the early onset phenotype in the twins. The same amino acid substitutions had previously been identified as shared risk-modulating factors for Crohn’s disease and Parkinson’s disease. To evaluate the functional impact of the LRRK2 mutations, we employed genome editing in RAW264.7 cells. Cells expressing the LRRK2 variants displayed reduced respiratory burst and apoptosis following mycobacterial challenge. Moreover, the BCG-induced respiratory burst was significantly lower in LRRK2 wild-type-expressing cells transfected with NOD2 R702W compared with NOD2 wild-type constructs. Employing co-immunoprecipitation, we showed that LRRK2 and NOD2 wild-type proteins interact in RAW cells. This interaction was independent of the LRRK2 variants but strongly reduced for NOD2 R702W. However, N-glycolyl MDP-triggered RIP2 phosphorylation and NF-kB activation were additively reduced by both LRRK2 and NOD2 mutations. Finally, we observed a joint effect of LRRK2 and NOD2 variants on cytokine/chemokine secretion with the most significant reduction of secretion observed for the mutant genotypes carried by the twins. These data demonstrated the pleiotropic effects of LRRK2 and NOD2 in response to mycobacterial infection consistent with a role of the identified mutations in the development of early onset leprosy.One Sentence Summary Variants of NOD2 and LRRK2 shared between early onset leprosy, Parkinson’s and Crohn’s disease jointly impact the anti-mycobacterial host response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Canadian Institutes of Health Research (CIHR) to ES [FDN-143332] and from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) to MTM [Universal/2011]. MTM is supported by CNPq grant Productivity (PQ) 304368/2018-0. MD-S was supported by a fellowship [3407/15-2] from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Ministry of Education of Brazil. JM and AA are supported by Laboratoire d'Excellence Integrative Biology of Emerging Infectious Diseases [grant ANR-10-LABX-62-IBEID], the Investments for the Future program [ANR-10-IAHU-01] and MYCOPARADOX ANR project [ANR16-CE12-0023]. The provision of M. leprae was supported by National Institute of Allergy and Infectious Diseases Interagency Agreement IAA 15006-004. This research was supported through resource allocation in the Cedar (WestGrid) and Guillimin (Calcul Québec) high performance computing clusters by Compute Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants (or their legal representatives) agreed to participate and signed written informed consent, under protocols approved by local institutional review boards: Pontifícia Universidade Católica do Paraná (169.382) and Federal University of Piauí (657.779).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials.